Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

22%

Ph phase_2

78%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 2Efficacy & side effects

7(77.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(1)

Detailed Status

Not yet recruiting8

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (22.2%)

Phase 27 (77.8%)

Trials by Status

completed111%

not_yet_recruiting889%

Recent Activity

0 active trials

Showing 5 of 9

not_yet_recruitingphase_2

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

NCT05684159

not_yet_recruitingphase_2

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05731050

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT05646563Phase 2

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Not Yet Recruiting

NCT06454110Phase 2

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

Not Yet Recruiting

NCT05647811Phase 1

Study of NM8074 in Adult C3 Glomerulopathy Patients

Not Yet Recruiting

NCT05684159Phase 2

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

Not Yet Recruiting

NCT05731050Phase 2

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Not Yet Recruiting

NCT06887738Phase 2

Study of NM8074 in Patients with Dermatomyositis (DM)

Not Yet Recruiting

NCT05646524Phase 2

Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Not Yet Recruiting

NCT06226662Phase 2

Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

Not Yet Recruiting

NCT05642546Phase 1

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9